Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) Debt to Equity (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Debt to Equity for 12 consecutive years, with $0.44 as the latest value for Q4 2025.

  • Quarterly Debt to Equity changed N/A to $0.44 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.44 through Dec 2025, changed N/A year-over-year, with the annual reading at $0.44 for FY2025, N/A changed from the prior year.
  • Debt to Equity hit $0.44 in Q4 2025 for Ligand Pharmaceuticals, down from $0.47 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.47 in Q3 2025 to a low of $0.09 in Q3 2022.
  • Historically, Debt to Equity has averaged $0.23 across 3 years, with a median of $0.14 in 2022.